Section 32
Section 32 is a California-based venture capital firm founded in 2017 by Bill Maris, who previously served as the CEO of Google Ventures. The firm focuses on early-stage investments in the life sciences, healthcare, and technology sectors across the United States. With a preference for investing between $5 million and $10 million in 25 to 30 companies, Section 32 seeks to support innovative projects that have the potential to significantly enhance the human condition. The firm operates primarily from San Diego and has raised a total of $150 million for its investment activities, targeting advancements in areas such as artificial intelligence, cybersecurity, fintech, and biotechnology. Through its strategic investments, Section 32 aims to accelerate the discovery, development, and distribution of transformative technologies.
MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.
Autobahn Therapeutics, Inc. develops small molecule therapies for the treatment of central nervous system (CNS) disorders. The company develops ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS), and adrenomyeloneuropathy (AMN). Autobahn Therapeutics, Inc. was formerly known as Llama Therapeutics, Inc. and changed its name to Autobahn Therapeutics, Inc. in December 2019. The company was incorporated in 2017 and is based in San Diego, California.